Stroke; a journal of cerebral circulation
-
Multicenter Study Clinical Trial
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01654445.
-
Randomized Controlled Trial
Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis.
Stenting has been used as a rescue therapy in patients with intracranial arterial stenosis and a transient ischemic attack or stroke when on antithrombotic therapy (AT). We determined whether the stenting versus aggressive medical therapy for intracranial arterial stenosis (SAMMPRIS) trial supported this approach by comparing the treatments within subgroups of patients whose qualifying event (QE) occurred on versus off of AT. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00576693.
-
Rupture of intracranial aneurysms (IAs) causes subarachnoid hemorrhage, leading to immediate death or severe disability. Identification of the genetic factors involved is critical for disease prevention and treatment. We aimed to identify the susceptibility genes for IAs. ⋯ ADAMTS15 is a candidate gene for IAs.
-
Specialized management of patients with stroke is not available in all hospitals. We evaluated whether prehospital management in the Stroke Emergency Mobile (STEMO) improves the triage of patients with stroke. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01382862.